“Here’s to the crazy ones — the misfits, the rebels, the troublemakers, the round pegs in the square holes. The ones who see things differently — they’re not fond of rules. You can quote them, disagree with them, glorify or vilify them, but the only…

“Here’s to the crazy ones — the misfits, the rebels, the troublemakers, the round pegs in the square holes. The ones who see things differently — they’re not fond of rules. You can quote them, disagree with them, glorify or vilify them, but the only thing you can’t do is ignore them because they change things. They push the human race forward, and while some may see them as the crazy ones, we see genius, because the ones who are crazy enough to think that they can change the world, are the ones who do.” - Steve Jobs

About Us

our origin story…

Raphael Capital was started in 2006 by David Kolb after over a decade long career on Wall Street where he completed over $2.6 billion in transactions. He has been the founder and CEO of six life science companies across a variety of therapeutic areas from neurology and oncology to wound care and gastrointestinal disease. David has also been an inventor on six pending/issued patents in the fields of neurology and oncology. He enjoys spending time with his family, listening to 80’s British alternative music, running, tennis and basketball and rooting for his beloved New York Jets.

David is a creative and flexible business partner. He clearly articulates his business objectives, but recognizes the constraints of the other party in order to work in partnership towards a win-win solution. I look forward to a productive working relationship with his company as they move towards the commercialization of our technology.
— David Lewin - Yale University Office of Technology Development
David has a deep understanding of the Healthcare market, and this results in technologies that are truely applicable to the changing environment of Healthcare today. He belives in partnerships, not deals and that makes working with David easy and productive....
— Clifford Murphy - BD Director, Molnlycke Health Care
David puts the partners interest in the for front and pays attention to details than will make a difference in the transaction. He is very service oriented and strives to meet meet the client needs on a daily basis. I also find that he is honest, direct and ethical.
— Jeff Thompson - Partner, HealthEdge Investment Partners
I worked with David on a slate of potential out-licensing transactions and found him to be an excellent counterpart. I continue to exchange business ideas with David and have tapped into his extensive network. I highly recommend David as licensing partner for anybody in the corporate BD or private equity industries.
— Mohan Chukkapalli - Business Development, Pfizer
David founded Insero based around technology developed here at Harvard. He is very knowledgeable and his transactional experience made the process of finding a mutually acceptable deal relatively easy. I would be happy to work with David again and look forward to seeing great progress from Insero.
— Michal Preminger - Harvard Medical School Technology Transfer
Recently UGA licensed a technology to a start-up company that David hepted to form. Our negotiation process was speedy and David was atune to the needs of a company-university partnership rather than a company-to-company partnership. David always make sure to keep the ball rolling and I look forward to continuing our relationship.
— Rachael Reiman Widener - University of Georgia Technology Transfer
David is well connected and in constant contact. He provides excellent opportunities and thorough follow through. David’s understanding of the market and client focused attitude make him a great choice for business development and investment banking needs.
— Bob Booth - CEO, Aquasis Biocorp LLC